Evidence map›Paper›PMID 38543942›Full record

ArticleVaccines2024

SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.

Bo-Hung Liao, Louise Platen, Myriam Grommes, Cho-Chin Cheng, Christopher Holzmann-Littig, Catharina Christa, Bernhard Haller, Verena Kappler, Romina Bester, Maia Lucia Werz and 9 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Bo-Hung LiaoInstitute of Virology, TUM School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.
Louise PlatenDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.ORCID 0009-0004-7223-7653
Myriam GrommesDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Cho-Chin ChengInstitute of Virology, TUM School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-5951-2743
Christopher Holzmann-LittigDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-9849-148X
Catharina ChristaInstitute of Virology, TUM School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.
Bernhard HallerInstitute of AI and Informatics in Medicine, TUM School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-9723-393X
Verena KapplerDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Romina BesterInstitute of Virology, TUM School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.
Maia Lucia WerzDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Eva PlatenKidney Center Eifel Dialyse, 53894 Mechernich, Germany.ORCID 0000-0003-1621-0232
Peter EggererKfH Kidney Center Harlaching, Munich-Harlaching, 81545 Munich, Germany.
Laëtitia TréguerKfH Kidney Center, 83278 Traunstein, Germany.
Claudius KüchleDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Christoph SchmadererDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Uwe HeemannDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Lutz RendersDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Ulrike ProtzerInstitute of Virology, TUM School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-9421-1911
Matthias Christoph BraunischDepartment of Nephrology, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0001-8527-0699
TUM Klinikum · DETechnical University of Munich · DEHelmholtz Zentrum München · DEMünchen Klinik Harlaching · DEPHV Dialysezentrum · DE

Funding

Netzwerk Universitätsmedizin (NUM), COVIM platform 01KX2021the European Union's Horizon 2020 research and innovation programme no. 848223the Helmholtz Association's Initiative and Networking Fund KA1-Co-02 'COVIPA'
6 · The paper itself

Abstract

backgroundHemodialysis patients have reduced serologic immunity after SARS-CoV-2 vaccination compared to the general population and an increased risk of morbidity and mortality when exposed to SARS-CoV-2.

methodsSixty-six hemodialysis patients immunized four times with the original SARS-CoV-2 vaccines (BNT162b2, mRNA-1273) either received a booster with the adapted Comirnaty Original/Omicron BA.4-5 vaccine 8.3 months after the fourth vaccination and/or experienced a breakthrough infection. Two months before and four weeks after the fifth vaccination, the live-virus neutralization capacities of Omicron variants BA.5, BQ.1.1, and XBB.1.5 were determined, as well as neutralizing and quantitative anti-SARS-CoV-2 spike-specific IgG antibodies.

resultsFour weeks after the fifth vaccination with the adapted vaccine, significantly increased neutralizing antibodies and the neutralization of Omicron variants BA.5, BQ.1.1, and XBB.1.5 were observed. The increase was significantly higher than after the fourth vaccination for variants BQ.1.1 and BA.5. Of all analyzed variants, BA.5 was neutralized best after the fifth vaccination. We did not see a difference in humoral immunity between the group with an infection and the group with a vaccination as a fifth spike exposure. Fivefold-vaccinated patients with a breakthrough infection showed a significantly higher neutralization capacity of XBB.1.5.

conclusionA fifth SARS-CoV-2 vaccination with the adapted vaccine improves both wild-type specific antibody titers and the neutralizing capacity of the current Omicron variants BA.5, BQ.1.1, and XBB.1.5 in hemodialysis patients. Additional booster vaccinations with adapted vaccines will likely improve immunity towards current and original SARS-CoV-2 variants and are, therefore, recommended in hemodialysis patients. Further longitudinal studies must show the extent to which this booster vaccination avoids a breakthrough infection.

Indexed as

BQ.1.1hemodialysisin vitro viral neutralizationOmicron BA.5SARS-CoV-2updated Comirnaty Original/Omicron BA.4-5 vaccineXBB.1.5

Identifiers

PMID38543942
PMCPMC10974241
OpenAlexW4392846116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.